BioCryst Pharmaceuticals Inc (NASDAQ:BCRX)

8.53
Delayed Data
As of May 18
 -0.38 / -4.27%
Today’s Change
7.61
Today|||52-Week Range
19.99
-38.41%
Year-to-Date
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
May 18 / Zacks.com - Paid Partner Content
BioCryst Pharmaceuticals (BCRX) Q1 2022 Earnings Call Transcript
May 05 / MotleyFool.com - Paid Partner Content
Why BioCryst Stock Lost Nearly 4% of Its Value Today
May 05 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close8.90
Today’s open8.68
Day’s range8.33 - 8.91
Volume3,195,909
Average volume (3 months)4,940,033
Market cap$1.6B
Data as of 4:01pm ET, 05/18/2022

Growth & Valuation

Earnings growth (last year)+5.98%
Earnings growth (this year)-25.86%
Earnings growth (next 5 years)+4.47%
Revenue growth (last year)+782.38%
P/E ratioNM
Price/Sales15.78
Price/Book--

Competitors

 Today’s
change
Today’s
% change
TVTXTravere Therapeutics...-0.63-2.45%
AUPHAurinia Pharmaceutic...-0.24-2.10%
IBRXImmunitybio Inc-0.28-6.93%
----
Data as of 4:01pm ET, 05/18/2022

Financials

Next reporting dateAugust 9, 2022
EPS forecast (this quarter)-$0.34
Annual revenue (last year)$157.2M
Annual profit (last year)-$184.1M
Net profit margin-117.11%

Profile

Sector
Health Technology
Industry
Biotechnology
No executives to display
Corporate headquarters
Durham, North Carolina

Forecasts